In plain English
Tirzepatide copies two natural gut hormones, GLP-1 and GIP, that help control appetite and blood sugar. Because it works on both, it tends to produce more weight loss than medicines that act on GLP-1 alone. It is injected once a week.
What it's used for
- Weight management in adults (Zepbound)
- Type 2 diabetes: improving blood-sugar control (Mounjaro)
- Moderate to severe obstructive sleep apnea in adults with obesity (Zepbound)
- Also being studied for heart failure, fatty liver disease and kidney disease
Benefits
In human studies, tirzepatide has shown:
- About 21% average weight loss over 72 weeks at 15 mg weekly (SURMOUNT-1)
- About 20% average weight loss versus about 14% with semaglutide in a head-to-head study (SURMOUNT-5)
- Larger drops in HbA1c than semaglutide 1 mg (SURPASS-2)
- Far fewer breathing interruptions during sleep in people with sleep apnea
- Strong appetite control with once-weekly dosing
How it works
In simple terms: tirzepatide pulls two “I’m full” levers instead of one.
It is a single molecule that activates both the GIP receptor and the GLP-1 receptor. GLP-1 activity slows stomach emptying, reduces hunger in the brain and boosts insulin release when blood sugar is high. GIP activity adds to the insulin effect and appears to affect fat tissue and nausea signalling, which may explain why the combination produces more weight loss. Like semaglutide, it carries a fatty-acid chain that binds albumin in the blood, giving it a roughly five-day half-life and once-weekly dosing.
Development history
Tirzepatide was developed by Eli Lilly as the first dual GIP/GLP-1 peptide.
- 2022: Mounjaro is FDA-approved for type 2 diabetes.
- 2023: Zepbound is FDA-approved for weight management.
- 2024: Zepbound is approved for obstructive sleep apnea in adults with obesity, and single-dose vials join the pens.
Typical protocols
Branded tirzepatide comes in pre-filled pens and single-dose vials. This schedule follows the prescribing label.
| Step | Weekly dose | Notes |
|---|---|---|
| Start | 2.5 mg for 4 weeks | A starter dose to let the stomach adjust |
| Step up | +2.5 mg | No sooner than every 4 weeks, as tolerated |
| Maintenance: weight or diabetes | 5, 10 or 15 mg | 15 mg is the maximum |
| Maintenance: sleep apnea | 10 or 15 mg |
Tirzepatide is also available as powder in vials. Users report following the same 2.5 mg start and 4-week steps, using the calculator below to convert each mg dose into syringe units.
Cycling
Tirzepatide is not cycled; it is used long term. In the SURMOUNT-4 trial, people who switched to placebo after 36 weeks regained much of the lost weight, while those who continued kept losing. If more than a couple of weeks of doses are missed, prescribers often restart at a lower dose.
Administration options
Subcutaneous injection once a week in the belly, thigh or upper arm, on the same day each week, with or without food. If needed, the weekly day can be changed as long as doses are at least 3 days apart.
Reconstitution and dosing calculator
Pens and branded vials are ready to use. The calculator below is for tirzepatide powder, commonly mixed with 2 mL of bacteriostatic water.
Draw your syringe to
– units
- Volume to draw
- –
- Concentration
- –
- Each unit holds
- –
- Doses per vial
- –
Show the math
This tool does arithmetic only. It does not choose a dose or confirm that any substance is right for you. Double-check every result against your syringe and your clinician’s instructions.
Side effects and safety
- Most common: nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, lower appetite and injection-site reactions. These are usually worst after starting or raising the dose.
- The prescribing label warns about thyroid C-cell tumors seen in rodents. People with a personal or family history of medullary thyroid cancer or MEN 2 syndrome should not use it.
- Other risks listed on the label: pancreatitis, gallbladder problems, low blood sugar when combined with insulin or sulfonylureas, kidney strain from dehydration, serious allergic reactions, and risk of inhaling stomach contents during anesthesia.
- Hormonal birth control taken by mouth may work less well; the label advises a backup method for 4 weeks after starting and after each dose increase.
- Not for use during pregnancy.
Common stacks
- Not combined with semaglutide, retatrutide or other GLP-1 peptides, since they overlap.
- Users report pairing it with BPC-157, or with growth hormone peptides to help hold on to muscle.
Storage
Pens and vials: refrigerate at 2–8 °C (36–46 °F); do not freeze. Short periods at room temperature are allowed per the label.
Powder vials: keep cold and dry; after mixing, refrigerate and protect from light.
Compare with
- Semaglutide: GLP-1 only; somewhat less average weight loss in head-to-head studies, with proven heart-risk reduction.
- Retatrutide: adds glucagon activity on top of GLP-1 and GIP, with larger weight loss in studies.
- Mounjaro vs Zepbound: same peptide, different branding and uses.
Frequently asked questions
Is Mounjaro the same as Zepbound?
Yes, both are tirzepatide. Mounjaro is used for type 2 diabetes; Zepbound for weight management and sleep apnea.
Why start at 2.5 mg if it barely works?
The first month lets your stomach adjust. Skipping it greatly raises the chance of nausea and vomiting.
Can I switch from semaglutide to tirzepatide?
Many people do. There is no exact conversion; the starting tirzepatide dose is usually chosen based on how well the previous dose was tolerated.
How much weight do people lose?
Results vary. Study averages were roughly 15–21% depending on dose.
References
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
- Frías JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
- Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025.
- Mounjaro and Zepbound (tirzepatide), US prescribing information, Eli Lilly and Company.